OR WAIT null SECS
June 09, 2025
Article
Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.
June 03, 2025
Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.
May 29, 2025
The FDA approves hydrocortisone oral solution for pediatric adrenal insufficiency, enhancing dosing accuracy and ease for young patients and caregivers.
May 27, 2025
Prothena halts birtamimab development after missing key Phase 3 trial endpoints for AL amyloidosis, prompting workforce reductions and cost-cutting measures.
May 24, 2025
Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.
May 19, 2025
Olezarsen shows promising results in reducing triglyceride levels for patients with moderate hypertriglyceridemia, offering hope for better cardiovascular health.
May 15, 2025
Elevated lipoprotein(a) levels significantly increase the risk of recurrent cardiovascular events, highlighting the need for effective LDL-C-lowering therapies.
May 08, 2025
Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.
MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.
May 07, 2025
NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.
